Hair loss treatment has come a long way, and dermatologist Marc Avram, MD, wants both patients and clinicians to take notice. Speaking at the Masters of Aesthetics Symposium in San Diego, Avram outlined a growing toolkit that spans topical and oral medications, regenerative therapies, and surgical options — all capable of not just slowing hair loss but actually regrowing hair.

Topical minoxidil remains the only FDA-approved option for both male and female androgenetic alopecia, but its biggest challenge is compliance — it takes 8–12 months to show full results. Low-dose oral minoxidil (LDOM) is gaining traction as a convenient, affordable alternative, though side effects like hypertrichosis, dizziness, and edema warrant monitoring. Finasteride remains effective but is declined by roughly a third of male patients due to concerns about post-finasteride syndrome — a rare but poorly quantified risk involving persistent mood and sexual side effects.

For patients who prefer to skip daily meds, low-level laser therapy, PRP (platelet-rich plasma), and hair transplant surgery (FUE or FUT) are viable alternatives, each with distinct trade-offs.

Key Takeaways:

• Topical minoxidil requires 8–12 months for full effect — counsel patients early to prevent dropout
• LDOM is effective and inexpensive; hypertrichosis is the most common side effect (15.1%)
• Topical finasteride carries the same risk profile as oral finasteride
• Hair transplant surgery does not halt ongoing hair loss — patient education is critical

Why it matters: With a wide range of effective options now available, the challenge has shifted from what to treat with to how to match the right therapy to the right patient — and keep them on it long enough to work.